论文部分内容阅读
目的:通过对比观察葶苈子不同产品免煎颗粒剂干预实验性COPD大鼠支气管、肺组织损伤及炎症反应的作用;参与实验性肺源性心脏病大鼠细胞外基质代谢紊乱、肺动脉高压、右心肥厚病理修复的药效差异。评估免煎颗粒剂的应用前景和问题。方法:通过4周香烟烟熏制备大鼠实验性COPD动物模型,于第3周始给药2周,实验第29天处死大鼠;通过组织病理切片进行支气管、肺形态学及计量观测,硝酸还原酶法检测血清NO水平,ELISA kit检测血清ET-1水平。四周烟熏结合一次性腹腔注射野百合碱制备大鼠肺源性心脏病模型,给药两周,于实验开始第57天处死大鼠,进行组织病理学观测,应用硝酸还原酶法检测血清NO水平,ELISA kit检测血清BNP、MMP-9、TIMP-1水平。结果:对实验性COPD干预效应:与模型组相比,T高剂量组能够明显抑制平均内衬间隔增厚(P<0.05)降低血清ET-1水平(P<0.01),L高剂量组血清NO水平显著降低(P<0.01);T高剂量组血清ET-1、较K、L高剂量组显著下降(P<0.05),T高剂量组血清NO水平较L高剂量组有意升高(P<0.05);T血清ET-1水平、K及L干预大鼠血清NO水平高剂量组较中剂量组有意降低(P<0.01,P<0.05,P<0.05)。对实验性肺源性心脏病干预效应:与模型组相比,T可有效降低大鼠右心肥厚指数、血清MMP-9水平(P<0.01);K组血清BNP、MMP-9水平的降低具显著性(P<0.05,P<0.01)。L对大鼠血清BNP水平、右心肥厚指数的干预具显著性(P<0.01,P<0.05)。T血清BNP水平较LS组明显降低(P<0.05),K较L大鼠血清MMP-9水平显著下降(P<0.05)。结论:产品间存在药效差异。T产葶苈子免煎颗粒剂可有效抑制实验性COPD大鼠支气管的炎症反应与肺组织损伤;三产品可有效缓解实验性肺心病模型的肺血管损伤、细胞外基质代谢紊乱、右心肥厚,延缓疾病进程。
OBJECTIVE: To observe the effect of different decoction of Radish on the bronchial and lung tissue injury and inflammatory reaction in rats with experimental COPD by comparing the effects of different decoction of Radish and decocting tablets on the metabolism of extracellular matrix, pulmonary hypertension, Right ventricular hypertrophy pathological differences in efficacy. Evaluate the application prospects and problems of the decocted granules. METHODS: The animal model of experimental COPD was established by cigarette smoking for 4 weeks. The rats were sacrificed on the 29th day after the first 3 weeks of the experiment. The bronchial and lung morphology and measurement were observed by histopathological examination. Serum NO levels were measured by reductase method and serum ET-1 levels were detected by ELISA kit. Four weeks after the administration of monocrotaline combined with a single intraperitoneal injection of monocrotaline, a rat model of pulmonary heart disease was prepared and administered for two weeks. Rats were killed on the 57th day after the start of the experiment for histopathological observation. Nitric acid reductase The levels of serum BNP, MMP-9 and TIMP-1 were detected by ELISA kit. Results: Compared with the model group, T high-dose group could significantly inhibit the increase of serum ET-1 level (P <0.05), L-high dose group (P <0.01). The levels of serum ET-1 and K, L in high-dose T group were significantly lower than those in high-dose L group (P <0.05) (P <0.05). The level of serum ET-1 in T group and the level of serum NO in K and L groups were significantly lower than those in middle-dose group (P <0.01, P <0.05, P <0.05). Interventional effect on experimental pulmonary heart disease: Compared with the model group, T can effectively reduce right ventricular hypertrophy index and serum MMP-9 level (P <0.01); decrease serum BNP and MMP-9 level in K group Significant (P <0.05, P <0.01). L had significant effects on serum BNP level and right ventricular hypertrophy index (P <0.01, P <0.05). T serum BNP levels were significantly lower than LS group (P <0.05), K serum L-serum MMP-9 levels were significantly decreased (P <0.05). Conclusion: There are differences in efficacy between products. T-producing 葶 苈 sub-decoction granules can effectively inhibit bronchial inflammation and lung tissue damage in experimental COPD rats; three products can effectively alleviate the experimental pulmonary heart disease model of pulmonary vascular injury, extracellular matrix metabolism disorders, right ventricular hypertrophy , Delay the disease process.